Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

ASHLAND, Massachusetts, October 8 /PRNewswire/ --

- Acceptance Will Reduce Animal Use in Cosmetics and Chemicals Testing

MatTek Corp. today announced that results of a recently completed US and European multi-laboratory "catch-up" validation study on MatTek's EpiDerm in vitro human skin tissue equivalent. The test results demonstrated the required sensitivity and specificity for EpiDerm to be accepted as a validated alternative to animal testing for determining human skin irritation by the European ECVAM Scientific Advisory Committee (ESAC).

IRVINE, California, October 8 /PRNewswire/ --

- New Game in Development

GamersFirst (http://www.gamersfirst.com), a service of K2 Network and one of today's most popular free-to-play online game publishers, announces a development partnership for an original game with A2M, the largest independent game developer in Canada.

GamersFirst and A2M will be working together on an unannounced social gaming title. This new game will be available in late 2009 and continues the pledge of GamersFirst expanding its industry presence into the development of original titles.

COPENHAGEN, October 8 /PRNewswire/ --

- Review Zanolimumab Program to be Discontinued and Headcount to be Reduced

- Summary: Genmab Announces the Results of its Portfolio Review; Zanolimumab Program to be Discontinued and the Company Will Reduce the Number of Employees

Genmab A/S (OMX: GEN) announced today that it is discontinuing development of zanolimumab (HuMax-CD4(R)). In addition, as a result of a portfolio review and assessment of the organization, Genmab is reducing its headcount by 101 positions.

TORONTO and LONDON, October 8 /PRNewswire/ --

- Former Callidus Vice President Joins Varicent to Head Varicent's Global Expansion

Varicent Software, an innovator and provider of sales performance management (SPM) solutions, today announced the appointment of Andy Armstrong as Vice President and General Manager International.

Formerly Vice President and General Manager International with Callidus Software, a leading Incentive Compensation Management Software vendor, Armstrong's remit is to drive forward the global expansion of the Toronto-based company.

BRUSSELS, October 8 /PRNewswire/ -- In the light of the upcoming Energy Council meeting this Friday 10 October, the European Wind Energy Association (EWEA) has sent an open letter to French Energy Minister Borloo.

EWEA expresses its concern about a proposed 'review clause' in the Renewable Energy Directive, and underlines the importance of priority grid access for renewables. The letter also addresses some of the other key issues on the table, such as the internal electricity market, grid integration and EU competitiveness.

INDIANAPOLIS and ROUSSET, France, October 8 /PRNewswire/ --

- For Doubling of Processing Power, Upgrade to AT91SAM9G20